Clinical Trial Update: Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS [Phase 1, Phase 2]

View source ↗

Summary

Dose-escalation study of OXi4503 as a single agent and in combination with cytarabine, with subsequent Phase 2 cohorts planned for acute myeloid leukemia and my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CYTARABINE (CYTARABINE)
• OXi4503

Snippet

Sponsor: Mateon Therapeutics | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: UNKNOWN